A CONCEPT ON THE DEVELOPMENT OF BUPRENORPHINE AUTOINJECTOR FOR SELF AND EMERGENCY ADMINISTRATION
Objective: In natural and man-made disasters, pain and infection would increase morbidity and mortality. In these situations immediate treatment is mandatory and the drug has to be absorbed faster. An auto injector would be useful. The objective of this study was to develop an analgesic auto injector with buprenorphine.
Methods: The auto injector is a reusable device with a disposable drug cartridge, capable of injecting 1 or 2 ml of drug solution. Sterile water filled cartridges were made from a pharmaceutical company. Water was withdrawn from the cartridge under a laminar flow and buprenorphine hydrochloride was injected to make 0.05 mg/ml concentration. Sterility test was carried out before and after injecting buprenorphine in the cartridge by nutrient agar method and aerobic and anaerobic sterility test mediums. Buprenorphine was injected, intraperitoneally in rats through autoinjector and compared with manual injection for its efficacy as an analgesic using Eddyâ€™s hot plate.
Results: The water filled cartridge as well as the buprenorphine drug filled cartridge was found to be sterile as no growth was observed in the nutrient agar and no turbidity was observed in the sterility test mediums. The analgesic effect of buprenorphine by autoinjector was found to be significantly (Kruskal Wallis ANOVA) more than manual injection and control group (median analgesic time in seconds, Control-4.0; manual injectionâ€“7.0; autoinjectorâ€“12.0).
Conclusion: Water filled cartridge could be converted to drug filled cartridge aseptically. Buprenorphine administered through autoinjector was better as an analgesic than manual injection.
2. Andrew Luke Aswegan, September 2007. Our ethical duty is to relieve pain and suffering. American College of Emergency Physcian. Available from: http://www.acep.org/Clinical---Practice-Management/Our-Ethical-Duty-Is-to-Relieve-Pain-and-Suffering/. [Last accessed on 10 Apr 2015].
3. Pathak SM, Jindal AK, Verma AK, Mahen A. An epidemiological study of road traffic accident cases admitted in a tertiary care hospital. Med J 2014;70:32-5.
4. Nalini Vadivelu, Roberta L Hinesl. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interventions Aging 2008;3(3):421â€“30.
5. KD Tripathi. Essentials of Medical Pharmacology. 7th ed. New Delhi: Jaypee Brothers Medical Publishers; 2013.
6. Jason M. White. Pleasure into pain: The consequences of long-term opioid use. Addictive Behaviors 2004;29:1311â€“24.
7. Mark J McKeen, Sadeq A Quraishi. Clinical review of intravenous opioids in acute care. J Anesthesiol Clin Sci 2013: doi.org/10.7243/2049-9752-2-1. [Article in Press].
8. Vijayaraghavan R. Autoinjector device for rapid administration of life saving drugs in emergency. Def Sci J 2012;62(5):307â€“14.
9. Stephen F Kemp, Richard F Lockey, F Estelle R Simons. Epinephrine: the drug of choice for anaphylaxis vs statement of the world allergy organization. WAO J 2008;2:18-26.
10. Bassel Abou-Khalil, James Wheless, Joanne Rogin, Kevin D Wolter, Glenn C Pixton, Rajesh B Shukla, et al. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. Epilepsia 2013;54(11):1968â€“76.
11. Schoenen J, Bulcke J, Caekebeke J, Dehaene I, De Keyser J, Hildebrand G, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia 1994;14:55â€“63.
12. William Simonson. A new naloxone auto-injection device to treat opioid overdose. J Nurse Practioners 2014;35(5):381-2.
13. Peter Varunok, Eric Lawitz, Kimberly L Beavers, Gary Matusow, Ruby Leong, Nathalie Lambert, et al. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Preference Adherence 2011;5:587-99.
14. Neeti Jain, Pravin Kumar, Deo Kumar, Yogendra Mavai, R Vijayaraghavan. Development and evaluation of combined drug formulation for autoject-injector, for emergency application in organophosphate poisoning. Def Sci J 2012;62(2):105-11.
15. Maurizio Rossini, Salvatore De Vita, Clodoveo Ferri, Marcello Govoni, Giuseppe Paolazzi, Carlo Salvarani, et al. Golimumab: a novel anti-tumor necrosis factor. Biol Ther 2013;3(2):83â€“107.
16. N Tandon, R Bolce, A Naim, S Bolge, L Ellis, CT Piech, et al. PMS66 satisfaction with and preference for golimumab and its auto-injector among rheumatoid arthritis patients switched from adalimumab or etanercept. J Int Soc Pharmacoeconomics Outcome Res 2012;15(4):45-6.
17. To evaluate sarilumab SAR 153191 (REGN88)â€“Autoinjector device in patients with rheumatoid arthritis. Clinical Trials gov; 2014. Available from: https://clinicaltrials.gov/ ct2/show/NCT02057250. [Last accessed on 14 Jul 2015].
18. Medac pharma inc secures FDA approval of Rasuvo (methotrexate injection for rheumatoid arthritis, poly-articular-course juvenile idiopathic arthritis and psoriasis. Market watch; 2014. Available from; http://www.marketwatch. Com/story/medac-pharma-inc-secures-fda-approval-of-rasuvo-methotrexate-injection-for-rheumatoid-arthritis-poly-articular-course-juvenile-idiopathic-arthritis-and-psoriasis. [Last accessed on 14 Jul 2015].
19. Vijayaraghavan R, Selvaraj R, Krishna Mohan S, Gopi PG, Tharani CB. Haematological and biochemical changes in response to stress induced by the administration of amikacin injection by autoinjector in animals. Def Sci J 2014;64(2):99-105.
20. Ira L Mintzer MD, Mark Eisenberg MD, Maria Terra BA, Casey MacVane MD, MPH, David U, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Family Med 2007;5:146-50.
21. Simon Ducharme MD MSc, Ronald Fraser MD, Kathryn Gill PhD. Update on the clinical use of buprenorphine in opioid-related disorders. Canadian Family Physician 2012;58:37-41.
22. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquired Immune Defic Syndr 2011;56(1):22-32.
23. Likar R, Griessinger N, Sadjak A, Sittl R. Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain. Wien Med Wochenschr 2003;153(14):317-22.
24. Joseph Pergolizzi, Rainer H BÃ¶ger, Keith Budd, Albert Dahan, Serdar Erdine, Guy Hans, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone). Pain Practice 2008;8:287â€“313.
25. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13(3):219-30.
26. Attina G, Ruggiero A, Maurizi P, Arlotta A, Chiaretti A, Riccardi R. Transdermal buprenorphine in children with cancer-related pain. Pediatr Blood Cancer 2009;52(1):125-27.
27. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. J Pain Practice 2010;10(5):428-50.
28. Mellar P. Davis. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Supportive Oncol 2012;10(6):209-19.
29. Irith Wiegand, Kai Hilpert, Robert EW Hancock. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008;3(2):163-75.
30. Manu Chaudhary, Anurag Payasi. Emerging Metronidazole resistance in anaerobes and mapping their susceptibility behaviour. Am J Infect Dis 2014;10(2):56-63.
31. IFRC, International federation of red cross and red crescent societies, World Disasters Report 2013. Available from: http://www.ifrc.org/PageFiles/134658/WDR%202013%20complete.pdf. [Last accessed on 14 Jul 2015].
32. Jordan HT, Brackbill RM, Cone JE, Debchoudhury I, Farfel MR, Greene CM, et al. Mortality among survivors of the Sept 11, 2001, World Trade Center disaster: results from the world trade center health registry cohort. Lancet 2011;378(9794):879-87.
33. Disaster risk management for health mass casualty Management, Disaster Risk Management for health fact sheets key points global platform. Available from: http://www.who.int/hac/events/drm_fact_sheet_mass_casualty_management.pdf. [Last accessed on 14 Jul 2015].
34. Jafari N, Shahsanai A, Memarzadeh M, Loghmani A. Prevention of communicable diseases after disaster: A review. J Res Med Sci 2011;16(7):956-62.
35. Vijayaraghavan R, Jain N, Gautam A, Sharma M, Singh S, Kumar D, et al. Evaluation of the antidotal efficacy of atropine sulphate and pralidoxime chloride given by autoinjectors against nerve agent (sarin) toxicity. J Med C B R Def 2007;5(1):1-12.
36. Lamson MJ, Sitki-Green D, Wannarka GL, Mesa M, Andrews P, Pellock J. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. Clin Drug Invest 2011;31(8):585-97.
37. Berteau C, Schwarzenbach F, Donazzolo Y, Latreille M, Berube J, Abry H, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence 2010;4:379-88.
38. Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, et al. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Prefer Adherence 2011;5:587-99.
39. Warne LN, Beths T, Holm M, Carter JE, Bauquier SH. Evaluation of the perioperative analgesic efficacy of buprenorphine, compared with butorphanol, in cats. J Am Vet Med Assoc 2014;245(2):195-202.